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Patientswith inherited blood disorders (IBDs) like thosewith
hemophilia, sickle cell anemia, and thalassemia, have long
been exposed to the risk of acquiring blood borne infections
before adequate procedures for screening of donated blood
and manufacturing of virus-inactivated clotting factors pre-
parations were widely applied.1,2 Consequently, adult
patients with IBD are those with highest rates of infection
with the hepatitis C virus (HCV), a complication that con-
tributed to deteriorate the clinical status of many patients
who had long been exposed to an increased risk of end-stage
liver disease including hepatocellular carcinoma (HCC).3–6 In
the very unfortunate subset of patients who acquired
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Abstract Chronic infection with the hepatitis C virus (HCV) has long been the dominant
complication of substitution therapy in patients with inherited blood disorders and
the cause of anticipated death due to end-stage liver disease. In hemophilia, transmis-
sion of HCV with clotting factors concentrates started to be curbed in the mid-1980s
following the adoption of procedures of virus inactivation of concentrates based on
heat, whereas in the 1990s treatment of HCV infection with interferon monotherapy
was attempted, however, with little success. The advent of combination therapy of
interferon with ribavirin led to a substantial improvement of treatment outcome (40%
rate of cure), that however was still of limited efﬁcacy in patients with advanced liver
disease, those with high load of HCV genotype 1, and patients coinfected with the
human immunodeﬁciency virus. In this latter population, while the course of hepatitis
C was accelerated as a consequence of immunodeﬁciency, the advent of highly active
antiretroviral therapy led acquired immunodeﬁciency syndrome (AIDS) to decline and
hepatitis C to progressively emerge as a dominant cause of mortality, in parallel. In
patients with thalassemia, transfusion-related transmission of HCV was efﬁciently
interrupted in 1992 with the advent of sensitive screening tests for testing donors for
HCV, whereas treatment with interferon and ribavirin of infected thalassemics was
constrained by an increased risk of anemia due to the hemolytic properties of ribavirin
coupled with interferon-induced bone marrow suppression. The advent of safe and
potent regimens based on the oral administration of direct antiviral agents has
revolutionized therapy of HCV in patients with congenital blood diseases, providing
substantial clinical beneﬁts and making elimination of infection in these populations,
possible.
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transfusion-associated coinfection with the human immu-
nodeﬁciency virus (HIV), the course of hepatitis C has been
accelerated, in many cases precluding optimal adherence to
antiretroviral therapy, with deleterious consequences on the
course of HIV infection, as well.7,8 Less is known on the
course of hepatitis C in hemolytic disorders, where the
prevalence of HCV among persons with sickle cell anemia
and thalassemia (20–35%) varies widely.9 In this special
population, transfusion transmitted HCV infection was the
dominant cause of liver disease before sensitive screening
tests for HCV had become available, whereas the risk of
progressive liver disease is confounded by secondary iron
overload.
In the last two decades, the threat of transmission of HCV
(and HIV) with clotting factor preparations has progressively
dissolved following the advent of effective procedures for
manufacturing virus-free clotting factors coupled with the
implementation of screening for HCVof blood obtained from
both repeat volunteers and payed donors. More recently,
virus safety of replacement therapy has been implemented
by the availability of recombinant factors, leading to a
majority of the new generations of IBD patients to run a
HCV-free life.10–12 This is not a trivial point considering the
death toll payed by IBD patients before the advent of direct
antiviral agents (DAAs), when the only hope for a cure of
chronic HCV infection rested on the administration of inter-
feron (IFN) associated to ribavirin (RBV), i.e., a poorly toler-
ated regimen that was difﬁcult to apply in patients with
anemia and endowedwith limited antiviral efﬁcacy.13,14 The
advent of safe, potent, and user-friendly DAAs to treat HCV
has resulted in the dawn of a new era for adults with IBD,
making the elimination of HCV in this special population,
possible.
The Burden of Hepatitis C in Hemophilia
Starting in the 1970s, the hemophilia community was hit by
an epidemic of transfusion-associated hepatitis C (in those
times termed non-A, non-B hepatitis) as reﬁnements in
management and prevention of bleeding complications led
to an increased demand of substitution therapywith clotting
factors, that could only be satisﬁed by expanding the access
to highly infectious concentrates manufactured from large
plasma pools obtained from payed donors.1,2 One or two
decades later, between 50 and 80% of multitransfused
hemophiliacs resulted to be chronically infected with HCV
(HCV ribonucleic acid [RNA] seropositive), whereas only a
tiny minority of anti-HCV seropositive patients testing
repeatedly HCV RNA seronegative had had a spontaneous
recovery from an acute episode of transfusion-transmitted
hepatitis C.1,2 While the frequency of chronic HCV infection
appeared to be linearly correlated with the severity of the
clotting factor defect and hence with the intensity of the
transfusion history, the course of the infection began to be
delineated following the identiﬁcation of aworse outcome of
patients with a longer history of infection, those with HIV
coinfection (present in 25% of the population) and thosewith
environmental or life-style predictors of adverse outcome,
alcohol abuse, and metabolic syndrome above all.7,8,15 Inter-
estingly enough, multitransfused hemophiliacs were among
the ﬁrst HCV populations in whom occult infection with the
hepatitis B virus (HBV) (seropositivity for HBV deoxyribo-
nucleic acid [DNA] in HBsAg seronegative patients) was
recognized using molecular approaches, a condition that
was later associated with a worse outcome of hepatitis C
in ordinary patients.16
Not unexpectedly, hepatitis C in hemophiliawas frequently
associatedwith thehard-to-cure subtype “a”of thegenotype1
of HCV transmitted with clotting factors manufactured from
plasma of payed donors, particularly from the United States,
including individuals with risky behaviors.
In those same years, the importance of HCV as a cause of
death in hemophilia was clearly recognized. The ﬁnding that
HCV caused accelerated progression of HIV disease while
antiretroviral therapy was constrained in patients with liver
failure, led HCV to stand as an independent predictor of
worse prognosis in HIV-infected hemophiliacs.8,15,17 The
dramatic decrease of HIV-related morbidity and mortality
allowed also to recognize that the progression of liver disease
was accelerated in the presence of HIV in parallel with
increased HCV load. Prospective studies revealed sharp
differences in the prognosis of hepatitis C in relation to
HIV seropositivity: in one study, the 16-year cumulative
incidence of end-stage HCV among those with and without
HIV was 14 and 2.6%, respectively, whereas in more than one
study, HCC started to surface as a dominant complication of
long-standing infection with HCV.18,19 In a questionnaire-
based survey of 11,801 hemophilic patients from 30 centers
from U.S. and 24 from U.K., 10 patients with HCC were
identiﬁed, all with cirrhosis and a majority infected with
HCV.19 In two studies in Italy, the prevalence of HCC was
found to greatly exceed that expected in the general popula-
tion (360 vs. 7  100,000 individuals) and to be more
frequently clinically aggressive than in ordinary HCV
patients.20,21 Treatment of liver failure and HCC with liver
transplantation was successfully performed in several HCV-
infected hemophiliacs, resulting in global survival beneﬁts
and a cure of the underlying clotting factor defect.22 How-
ever, even if the bleeding risk of hemophilia did not inﬂuence
both listing to and outcome of liver transplantation com-
pared with nonhemophilic populations, the number of
hemophilic candidates to liver transplant has remained
limited, mainly because most hemophilic patients were
burdened by comorbidities which limit listing. The outcome
of liver transplantations performed for end-stage HCV, how-
ever, greatly beneﬁtted from the arrival of second-genera-
tion DAAs, whichmade prevention of recurrent hepatitis C, a
relevant cause of shortened survival of liver transplanted
patients, possible and associated to signiﬁcant survival
beneﬁts.23
Prevention and Therapy of Hepatitis C in
Hemophilia
Replacement therapy of hemophilia started in the late 1940s
with the infusion of fresh-frozen plasma to be replaced in the
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mid-1960s by cryoprecipitates pooled from a few to a max-
imum of 20 donors. The risk of transmitting blood borne
viruses sky rocketed in the early 1970s following the wide-
spread use of concentrates derived from large pools of
plasma obtained from 20,000 to 50,000 donors.1,2 In the
mid-1980s, the epidemic of HIV spread by contaminated
factor concentrates caused acceleration in the production of
factors sterilizedwith virucidal procedures, an approach that
had previously been deferred not to compromise the man-
ufacturing yield and hence patients’ access to replacement
therapy. Development of safe and effective procedures of
virus inactivation based on physical (dry and vapor heat,
ultraviolet [UV] light) and chemical (organic solvent and
detergent approaches), led in the mid-1980s to the market-
ing of safer factor concentrates that contributed to prevent
transmission of enveloped viruses, unfortunately not of the
naked ones.11,24 The risk of transmission of naked viruses
with inactivated concentrateswas testiﬁed by an outbreak of
hepatitis A virus (HAV) infection occurring among patients
infused with solvent-/detergent-treated factors that led to
promoteHAVvaccination as a standard of care in hemophilia,
too.25 More recently, the advent of recombinant factors has
further contributed to protect the hemophilia community
against the risk of transfusion-associated transmission of
blood borne viruses, including HCV.
Antiviral treatment of HCV-infected hemophiliacs was
ﬁrst attempted since the early 1990s, however, with little
success. The reason for this was the combined effect of IFN
monotherapy being the only, yet suboptimal, therapeutic
regimen available to treat HCV and the prevalence of hemo-
philiacs having such adverse predictors of treatment out-
come as the genotype 1 of HCV, high viral load, advanced
ﬁbrosis, and HIV coinfection. With all these premises, the
selection process to identify hemophilic patients eligible for
treatment included only those with persistently elevated
transaminases, well compensated liver disease, and commit-
ment to antiviral treatment. In the ﬁrst study of therapy, 16
patients were subcutaneously dosed with 3 million units
(MU) of IFN monotherapy administered three times a week
for 6 or 12 months,26 where however treatment response
could only be assessed combining assessment of serum
transaminases with histological evaluation. Although only
four patients reached a sustained biochemical response, i.e.,
normal values of transaminases, accompanied by improve-
ment of liver inﬂammation at histology, the study opened
the way to a series of investigations that evaluated the
efﬁcacy of different doses of IFN (between 3 and 6 MU) or
of an induction dose of 9 MU in regimens administered for 6
or 12 months.27–39 In general, the sample size of those
studies was small enrolling accurately selected patients.
Two studies only enrolled more than 50 patients, the major-
ity of whom were HIV seronegative and without relevant
comorbidities, i.e., not fully representative of real-life
patients. Using the more appropriate endpoint of HCV era-
dication (sustained virological response, SVR), the outcome
of antiviral therapy turned out to be disappointingly poor, as
the cure rates ranged between 0% and less than 15%, only. The
only exception was a study in Japan reporting 47% rate of
cure,31 a success rate, however, that was inﬂated by the
administration of high doses of IFN and enrolment of
patients infected with easy-to-cure genotype 2 or 3 of
HCV. Not surprisingly, major reasons accounting for the
suboptimal rates of virological response of hemophiliacs to
IFNwere the prevalence of high viral load, impaired immune
competence due to repeated exposure to allogenic serum
proteins, accumulation of HCV quasi-species as a result of
multiple infusions with infected concentrates, long duration
of infection, and high prevalence of genotype 1, all well
identiﬁed negative predictors of treatment outcome in non-
hemophilic populations.15 In hemophilia, IFN refractoriness
has also been associated to a change of HCVgenotype during
therapy, as it may result from infection with different clones
transmitted by multiple infusions of infected concentrates
that had different sensitivity to IFN.32 Coinfection with HIV
long standed as a dominant negative predictor of IFN
response too, as indicated by studies of monotherapy where
only 8% of HIV coinfected patients ultimately achieved virus
eradication.14 The response rates could signiﬁcantly be
improved following the combined administration of the
nucleoside analog RBV in both HIV positive and HIV negative
hemophiliacs, including previously nonresponders to IFN
monotherapy.40–43 In treatment naive populations, a cure
of the infection was in fact attained in 40% of the patients,
matching exactly the outcome of IFN therapy of nonhemo-
philic populations. While in two studies of retreatment of
nonresponders to IFN monotherapy, one-third of all treated
patients achieved a cure from HCV infection,44,45 the rates of
SVR were further optimized following the advent of pegy-
lated (Peg) IFN. This regimen combined with RBV led to
achieve 50% rates of SVR in the difﬁcult-to-cure patients
infectedwith HCVgenotype 1 and 4, and tomore than 80% in
the fewer, but easier-to-cure patients with HCV genotype 2
and 3.46,47 The downside of this regimen, however, was the
10% of patients who required dose reduction of either drug
due to the onset of signiﬁcant symptoms or complications
like anemia and neutropenia. As these adverse events
occurred more frequently in patients with advanced liver
ﬁbrosis compared with hemophiliacs with milder liver dis-
ease, this led to emphasize the recommendation for early
treatment of all-treatment naive patients lacking speciﬁc or
generic contraindications.48 Owing to the fact that the
progression of liver disease is accelerated in patients with
HIV coinfection, treatment guidelines endorsed by National
Institutes of Health (NIH), American Association for the
Study of Liver Diseases (AASLD), and the European Consen-
sus Conference in Paris, 2005, recommended 48weeks of Peg
IFN/RBV therapy in HIV coinfected patients, irrespective of
genotype, whenever the risk of serious liver disease was
judged to outweigh the risk of morbidity due to adverse
effects of therapy.49–51
In 2013, the therapeutic scenario of HCV was revolutio-
nized by the advent of safe and potent all-oral IFN-free
therapies, making the elimination of hepatitis C in hemo-
philia a realistic goal.52,53 The ﬁrst report in hemophilia
concerned a 24-week course of the NS5B polymerase inhi-
bitor sofosbuvir associated to the NS5A inhibitor daclatasvir
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to treat two HIV coinfected, treatment experienced hemo-
philiacs with end-stage HCV.54 A cure of the infection was
attained by both patients, without any signiﬁcant side effect,
whereas HIV infection had remained suppressed following
adjustment of antiretroviral therapy. In a study in the United
States, 120 patients with bleeding disorders were treated
with sofosbuvir associated to ledipasvir to treat genotype 1
and 4 HCV and to RBV to treat HCV genotype 2 and 3 leading
to > 95% rates of cure, irrespective of the presence of cir-
rhosis, prior IFN failure, or HIV coinfection.55 Similar results
were obtained in 43 Japanese patients treated with the same
combination therapy for 12 weeks, where the efﬁcacy was
not signiﬁcantly different between HIV positive and HIV
negative patients (95% vs. 100%), but apparently lower
(7/9) in patients with cirrhosis, suggesting that the addition
of RBV may be advantageous in patients with advanced liver
disease.56 The success rate of sofosbuvir/ledipasvir regimen
was universal in 14 patients with hemophilia or von Will-
ebrand disease who were treated with add-on RBV,57
whereas sofosbuvir/RBV was a suboptimal therapeutic regi-
men in Korean patients with HCV 2a/2b where two patients
experienced a viral breakthrough associated to emergence of
resistant variants58 (►Table 1).
More recently, the combination of an NS5A inhibitor
(elbasvir) and a protease inhibitor (grazoprevir) directed
against genotype 1 and 4 HCV, proved to be highly effective
in compensated patients including thosewith severe chronic
kidney disease, with and without cirrhosis, prior IFN failure,
and HIV coinfection.59 Among 47 patients with hemophilia
or vonWillebrand diseasewhowere randomized to immedi-
ate 12-week treatment, 42 (89%) achieved virus eradication,
the suboptimal response rate reﬂecting a patient with a
relapse attributable to baseline NS5 RASs conferring resis-
tance to elbasvir. These patients are considered liable to
respond following the addition of RBV or by extending to
16-week treatment with elbasvir/grazoprevir.60
The recent approval of second-generationmultigenotypic
DAAs with increased potency, different mechanisms of
action, and higher genetic barrier, might allow to treat a
broad range of patients reducing the need of tailoring the
regimen on the individual patient characteristics, an
approach that is expected to improve algorithms of HCV
therapy in hemophilia.61,62
The Burden of Hepatitis C in Thalassemia
Quality of life and survival of thalassemia patients living in
resource-rich countries have improved signiﬁcantly over the
past 30 years, following implementation of HCV screening of
donors and optimization of oral iron chelation regi-
mens.63–66 In those regions, this translated in a signiﬁcant
reduction of the risk of transfusion-transmitted HCV infec-
tion,67 at striking variance with developing countries where
standard of care approaches to obtain safe blood transfusions
are not fully implemented.68 In the West, cohorts of HCV
infected thalassemic patients are mainly composed by
adults, 80% of whom acquired the infection before 1990,69
whereas in the Middle East and Asia the same is true also for
many children or young adults (10–40% of all patients) who
acquired the infection in the last decades resulting in the
development of chronic liver disease70–77 (►Table 2). Not
unexpectedly, thalassemia population shows a wide geogra-
phical heterogeneity in the infecting HCV genotype: the
genotype 1 of HCV prevails in areas like Italy, whereas
genotype 3 is common among patients who live in Greece,
Australia, Iran, and India. Patients in Egypt and Lebanon are
more frequently infected by HCV genotype 4, whereas HCV
genotypes 5 and 6 infect a minority of Chinese patients,
only.9 While spontaneous recovery from acute infection
occurred in less than one-third of all patients, the rest
inexorably proceeding toward chronic liver disease, “favor-
able” genotypes of IL28b (IFNL3) single-nucleotide poly-
morphisms (SNPs) appear to associate with control of
infection in thalassemia patients favoring spontaneous clear-
ance of HCV infection and response to IFN with less propen-
sity to develop cirrhosis.78
While heart failure stands as a major cause of mortality in
thalassemia despite the switch from subcutaneous desfer-
rioxamine to oral chelation regimens,79,80 chronic liver dis-
ease due to HCV has long been a relevant complication of
Table 1 DAA treatment of HCV-infected patients with hemophilia or von Willebrand disease55–59
Author, y Patients HIV-
coinfected
(%)
Patients
with
cirrhosis
Genotypes DAA regimen Overall SVR SVR in HIV-
coinfected
Stedman et al, 2015 14 0/14 1 1a, 1b SOF/LDV þ RBV 14/14 (100%) –
Walsh et al, 2017 120 26/120 (22) 37 1a, 1b, 2, 4 SOF þ RBV
SOF/LDV
118/120 (99%) 25–26/26
(96–100%)a
Nagao and Hanabusa,
2017
43 20/43 (47) 9 1a, 1b, 4 SOF/LDV 41/43 (95%) 18/20 (90%)
Lee et al, 2017 30 0/30 4 1a, 1b, 2 SOF/LDV, DCV þ
ASV SOF þ RBV
28/30 (93%) –
Hézode et al, 2017 47 6/47 (9) n.d. 1a, 1b, 4 EBV þ GZR 42/47 (89%) 5/6 (83%)
Abbreviations: ASV, asunaprevir; DAA, direct antiviral agent; DCV, daclatasvir; EBV, elbasvir; GZR, grazoprevir; HCV, hepatitis C virus; HIV, human
immunodeﬁciency virus; LDV, ledipasvir; n.d., not done; RBV, ribavirin; SOF, sofosbuvir; SVR, sustained virological response.
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thalassemia care. This is the consequence of an interaction
between iron overload and chronic infection with HCV that
leads to progressive accumulation of ﬁbrosis in the liver,
thereby increasing the risk of end-stage liver disease. In a
retrospective analysis with liver biopsies of 126 transfusion-
dependent patients (mean age 17 years), advanced stages of
ﬁbrosis were detected in 32% out of 68 HCV-RNA positive
patients comparedwith only 4% out of 68 HCV-RNA negative
patients, withmale gender (odds ratio [OR]: 4.12) and serum
HCV-RNA (OR: 11.04) being independent predictors of
advanced liver ﬁbrosis. The propensity of iron to fuel pro-
gression of hepatitis C clearly emerged from a study where a
minority of HCV-RNA negative patients were found to have
severe ﬁbrosis in the presence of low liver iron load com-
pared with more patients with HCV and high liver iron
overload who had advanced liver ﬁbrosis. Another study
clearly highlighted how iron overload can be toxic to the liver
independently from HCV, as it showed that adequate chela-
tion therapy was able to prevent accumulation of liver
ﬁbrosis in thalassemia patients who were unaffected by
HCV.81
While liver biopsy has long been the gold standard for
quantifying inﬂammation, ﬁbrosis, and iron overload in the
liver of patients with liver disease of any etiology including
thalassemia, evaluation of liver stiffness through the non-
invasive technique of transient elastography has progres-
sively gained popularity to become nowadays a reliable
predictor of liver disease severity, particularly among
patients with chronic HCV infection.82 This approach, how-
ever, retains several limitations, one above all is the inability
to disentangle the quotas of stiffness related to ﬁbrosis
versus those attributable to other injuries including cell
necrosis and iron overload. Owing to the fact that thalasse-
mia patients may have liver stiffness values modiﬁed inde-
pendently of iron overload, combining magnetic resonance
imaging (MRI) with transient elastography might offer a
more reliable assessment of iron overload of the liver.83–85
In analogy with cohorts studies of ordinary patients, the
prevalence of cirrhosis in thalassemia patients in the United
States, Italy, and Greece ranged from 10 to 20%,6,78,86,87 and
not surprisingly, male sex, high HCV-RNA load, and high liver
iron concentration were all signiﬁcantly associated with
increased risk of cirrhosis and HCC. Of note, the incidence
of HCC in thalassemia patients has progressively increased
over the past 10 years, mainly as a consequence of a
signiﬁcant improvement of patient survival coupled with a
long history of HCV infection and liver iron overload, both
factors being well-recognized mediators of liver carcinogen-
esis.88 In a multicenter retrospective study performed in 52
Italian thalassemia centers, 22 patients were found to have a
HCC, the vast majority (70%) harboring serum HCV-RNA,
however, without data on the incidence rates of HCC in this
population.89 In a prospective study of surveillance with
abdominal ultrasound of 108 thalassemia patients (median
age 37 years, 72 with risk factors for HCC like iron overload,
HCV, hepatitis B, cirrhosis), two patients were found to
develop an HCC, with an estimated annual incidence rate
of 2%.90 In a recent report from 55 centers in Italy, 60 new
cases of HCC were identiﬁed among 5,855 thalassemia
patients (nearly the entire burden of thalassemia in Italy)
between 2002 and 2012. The cumulative incidence was
1.02% (95% conﬁdence interval [CI]: 0.78–1.3) with 32 cases
out of 4,248 patients with thalassemia major (0.75%; 95% CI:
0.52–1. 06) and 28 cases out of 1,607 patients with thalas-
semia intermedia (1.74%; 95% CI: 1.16–2.51). Forty-three
patients (69%) circulated serum HCV RNA, and 41 (66%) died
at the end of observation period, thereby conﬁrming chronic
infection with HCV to stand as a determinant of survival in
thalassemia patients.91
Treatment of Hepatitis C in Thalassemia
In the IFN era, thalassemia patients with chronic HCV infec-
tion were considered a “difﬁcult-to-treat” population,
because antiviral therapy was challenged by difﬁculties in
maintaining optimal dosing of IFN and RBV, owing to wor-
sening of anemia caused by RBV, which led to increased
demand of blood transfusions and increase of iron overload.
When IFNmonotherapywas the only therapeutic option, the
rates of cure of HCV were consistently less than 50% in all
treated patients, with preference for patients with moderate
liver ﬁbrosis, low liver iron concentration, and infectionwith
Table 2 Prevalence of HCV infection in thalassemia patients
References Year Geographical area Screened thalassemia
patients (number)
Mean age
(y)
Anti-HCV
(%)
Jang et al70 2017 Taiwan 67 26 37.5
Ahmed Kiani et a l71 2016 Pakistan 1,253 10 21.7
Jafroodi et al72 2015 Iran 1,113 26.1 13.6
Al-Naamani et al73 2015 Oman 200 23.1 41
Chakrabarty et al74 2014 Bangladesh 200 6 2
Hussein75 2014 Egypt 200 9 24
Mansour76 2012 Egypt 200 13 40
Al-Sweedan et al77 2011 Jordan 122 14 32.2
Abbreviation: HCV, hepatitis C virus.
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HCV genotype 2.92 With the advent of Peg-IFN associated to
RBV and treatment tailoring according to HCV genotype, the
only patients exceeding 50% rates of curewere those infected
bygenotype 2 ofHCV (60%), in the face, however, of increased
transfusion volumes needed to counteract RBV-induced
anemia.93 The current European Association for the Study
of the Liver (EASL) Clinical Practice Guidelines recommend
IFN-free regimens for the treatment of HCV infection in
patients with hemoglobinopathies, as DAAs have provided
> 90% rates of cure, irrespective of HCV genotype or history
of previous antiviral therapy.60 In a multicenter phase III
randomized trial, 95% (18/19) and 98% (40/41) of patients
with sickle cell disease and thalassemia, achieved a cure of
hepatitis C following 12-week treatment with elbasvir/gra-
zoprevir, respectively.94 In the 6 patients with a hepatitis
relapse, 4 with genotype 1a, 1 with genotype 1b, and 1 with
genotype 4, pretreatment NS5A and NS3 RAS were detected
in all patients at time of treatment failure. Serious adverse
events were reported in two patients only, one with thalas-
semia developing erosive gastritis and hypophosphatemia,
and another one with sickle cell disease developing a hemo-
lytic crisis. High rates of cure were conﬁrmed by an observa-
tional multicenter study95 of 61 thalassemia patients with a
mix of HCV genotypes (median age, 43 years) and advanced
liver disease (79% with cirrhosis) who were exposed to
sofosbuvir/RBV, SOF þ simeprevir  RBV, SOF þ daclatasvir
 RBV, SOF þ ledipasvir  RBV, and ombitasvir/paritapre-
vir-ritonavir þ dasabuvir  RBV. The overall rates of hepa-
titis cure were 90%, all DAA regimens were well tolerated,
and no major adverse events or drug–drug interactions
occurred. In a study in Italy,95 with sofosbuvir/ledipasvir in
100 patients with thalassemia major and HCV genotype 1 or
4, the cure rates were as high as 98%, whereas in another
observational study in Italy involving 139 patients, the rates
of curewere 94%, with three patients dying during the period
of observation for causes unrelated to DAAs, one patient not
achieving a virological response, and ﬁve (4%) relapsing after
the end of therapy.96 Interestingly, therapywith DAAwas not
associated with increased iron overload, whereas SVR
patients showed signiﬁcant reductions in ferritin values after
the end of antiviral therapy.
More than 2million people have been successfully treated
with generic DAA worldwide, and those regimens proved to
be as safe and effective as brand named DAA in 29 thalasse-
mia patients, too97 (►Table 3). The effectiveness of generic
DAAswas proven on a small number of thalassemia patients:
a cure of hepatitis C was achieved by all treated patients at
the expenses of a transiently increased transfusional volume
during antiviral therapy, particularly in those exposed to
RBV. These ﬁndings, therefore, align with reports in millions
of ordinary patients who have successfully been treatedwith
generic DAAs, suggesting that generics are a valuable option
for a cost-saving therapy of HCV in thalassemia in developing
regions that cannot afford the costs of brand named antiviral
therapies.98 All in all, the advent of IFN-free regimens
translated in a substantial change of the therapeutic scenario
of thalassemia care with the prospect of a signiﬁcant
improvement of the natural course of this complex disease
and hopefully of patient survival, too.99
Conclusion
The implementation of screening for HCV of donors and the
manufacture of virus-free concentrates of clotting factors
have progressively led to the interruption of HCV transmis-
sion to patientswith IBD,making this infection amore than a
rare event in the care of IBD.More recently, the advent of IFN-
free regimens based on DAA made treatment of hepatitis C
possible in every infected patient, including those who were
considered hard to cure with IFN. Thanks to these achieve-
ments, a generation of young, HCV-free patients with IBD is
cumulating everywhere in the world that represents a ﬁrst
stone in the building of a ﬁrewall against dissemination of
HCV, a ﬁrst step for the implementation of the ambitious
Table 3 Cure of HCV (SVR) in 420 thalassemia patients according to DAA regimens and HCV genotype59,94–97
DAA regimens Patients HCV1a
(n ¼ 75)
HCV1b
(n ¼ 262)
HCV2
(n ¼ 24)
HCV3
(n ¼ 31)
HCV4
(n ¼ 18)
SVR
SOF/LDV 175 11/12 152/156 7/7 170 (97.1%)
SOF/LDV þ RBV 16 5/5 8/9 2/2 15 (93.7%)
SOF þ DCV 49 3/3 9/9 12/13 19/20 3/4 46 (93.8%)
SOF þ DCV þ RBV 12 1/1 11/11 12 (100%)
OMB/PRV/r þ DSV þ RBV 2 1/1 1/1 2 (100%)
OMB/PRV/r þ DSV 18 1/1 16/17 17 (94.4%)
SOF þ SIM 29 4/4 18/20 5/5 27 (93.1%)
SOF þ SIM þ RBV 2 2/2 2 (100%)
GRZ þ ELB 103 43/47 44/46 97 (94.2%)
SOF þ RBV 14 1/1 1/2 11/11 13 (92.8%)
Overall SVR 70 (93.3%) 249 (95%) 23 (95.8%) 30 (96.7%) 17 (94.4%)
Abbreviations: DAA, direct antiviral agent; DCV, daclatasvir; DSV, dasabuvir; ELB, elbasvir; GZR, grazoprevir; HCV, hepatitis C virus; LDV, ledipasvir;
OMB, ombitasvir; PRV, paritaprevir; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir; SVR, sustained virological response.
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program of World Health Organization (WHO) aiming at the
elimination of viral hepatitis.100
Main Concepts and Learning Points
• Chronic infection with the hepatitis C virus (HCV) has
long been the dominant complication of substitution
therapy in patients with inherited blood disorders (IBD)
and the cause of anticipated death due to end-stage liver
disease.
• Transmissionofhepatitis Cwith clotting factors concentrates
was halted in the mid-1980s following the adoption of
procedures of virus inactivation of concentrates, whereas
in the early 1980s transfusion-transmitted hepatitis was
interrupted following the widespread adoption of HCV
screening of blood donors.
• The advent of direct antiviral agents (DAAs) has revolu-
tionized therapy of HCV providing substantial clinical
beneﬁts including prevention of liver-related mortality
and making elimination of hepatitis C in IBD patients,
possible.
• The process leading to the identiﬁcation of HCV as a
dominant cause of liver disease in hemophilia and the
approaches that allowed the transmission of HCV to IBD
populations to be halted.
• DAA treatment of hepatitis C as part of a microelimination
program targeting IBD is an effective intervention aiming to
prevent transmission of HCV to the general population.
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